This is a routine insider sale notice from the CEO. The 6,000-share amount is small relative to his likely holdings and the company's market cap. No immediate trading action warranted; monitor for any subsequent Form 4 filings to confirm execution and for any pattern of larger sales.
Price Chart
Executive Summary
Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals, filed a Form 144 on June 1, 2026, indicating intent to sell 6,000 shares of common stock. At the filing date, the proposed sale value was approximately $1.41 million, representing a modest portion of his likely total holdings. The filing is a routine insider sale notice and does not signal material concern given the CEO's ongoing role and the relatively small size relative to market cap.
Key Facts
- Filer: Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals
- Proposed sale: 6,000 shares of common stock
- Estimated value at filing: ~$1,410,720 (based on $235.12/share)
- Shares to be sold from stock options exercised on 03/05/2022
- Broker: Merrill Lynch
- Filing date: June 1, 2026; proposed sale date same day
- Recent insider activity (30d): 4 sells totaling $3.1M
Financial Impact
Proposed sale of 6,000 shares valued at ~$1.41M, representing approximately 0.01% of Jazz's $14.8B market cap
Risk Factors
- CEO selling could be misinterpreted as lack of confidence, though the small size mitigates this
- If this is part of a 10b5-1 plan, the signal is further neutralized
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-039499 |
| Document: 0001628280-26-039499-index.html | 0001628280-26-039499 |
| Document: 0001628280-26-039499.txt | 0001628280-26-039499 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | Press Release | $213.76 $211.97 | ▼ −0.84% | ▼ −1.36% | $210.99 (−1.30%) |
Oct 9, 2026 17d ago | 8-K | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 8, 2026 17d ago | 144 | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 6, 2026 19d ago | 144 | $231.19 $222.45 | ▼ −3.78% | ▼ −3.36% | $210.99 (−8.74%) |
Oct 1, 2026 24d ago | 144 | $235.67 $236.04 | ▲ +0.16% | ▼ −0.52% | $210.99 (−10.47%) |
Sep 15, 2026 5w ago | 8-K | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 14, 2026 5w ago | Insider Cluster | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 10, 2026 6w ago | Insider Cluster | $245.80 $245.87 | ▲ +0.03% | ▲ +0.47% | $210.99 (−14.16%) |
Sep 2, 2026 7w ago | Insider Cluster | $247.57 $246.81 | ▲ +0.30% | ▼ −0.08% | $210.99 (+14.78%) |
Aug 31, 2026 7w ago | 144 | $243.71 $245.57 | ▲ +0.76% | ▲ +0.32% | $210.99 (−13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers